Insider Selling: Progyny (NASDAQ:PGNY) EVP Sells $101,868.30 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 3,903 shares of the company’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the completion of the transaction, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. This represents a 4.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

NASDAQ PGNY traded up $0.08 during trading hours on Monday, reaching $25.52. The company’s stock had a trading volume of 1,011,013 shares, compared to its average volume of 1,407,611. The firm has a fifty day simple moving average of $27.76 and a 200-day simple moving average of $24.58. The stock has a market cap of $1.96 billion, a P/E ratio of 27.74, a P/E/G ratio of 1.76 and a beta of 0.99. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million for the quarter, compared to analyst estimates of $349.05 million. During the same period in the previous year, the firm posted $0.19 EPS. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, research analysts expect that Progyny, Inc. will post 1.25 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Leerink Partners set a $38.00 price objective on Progyny in a report on Wednesday, July 22nd. Weiss Ratings downgraded Progyny from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, August 31st. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. Canaccord Genuity Group set a $35.00 price target on Progyny in a research note on Friday, August 7th. Finally, Citizens Jmp raised their price objective on Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research report on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and a consensus price target of $34.36.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Progyny during the second quarter worth approximately $334,426,000. Fort Washington Investment Advisors Inc. OH increased its holdings in Progyny by 46.9% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares in the last quarter. Bank of America Corp DE increased its holdings in Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after purchasing an additional 511,609 shares in the last quarter. River Road Asset Management LLC lifted its stake in Progyny by 13.9% in the fourth quarter. River Road Asset Management LLC now owns 687,824 shares of the company’s stock valued at $17,663,000 after buying an additional 83,912 shares during the period. Finally, William Blair Investment Management LLC bought a new position in shares of Progyny during the 2nd quarter worth approximately $16,807,000. 94.93% of the stock is owned by institutional investors and hedge funds.

About Progyny

Progyny, Inc is a benefits management company that provides fertility and family-building solutions to employers and their employees. Its platform is designed to support individuals and couples pursuing fertility treatment, including in vitro fertilization, egg freezing, donor services, gestational surrogacy and adoption.

The company’s services combine access to a network of fertility specialists with personalized guidance, care coordination and treatment support. Progyny also offers pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.